Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06299098 · ClinicalTrials.gov registry record · Phase 2

A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss, Fat Loss, and Lean Mass Preservation

A Phase 2 study of Obesity, sponsored by Regeneron Pharmaceuticals.

Active
Registry status
Phase 2
Development phase
1,005
Enrollment target
20
Study locations

NCT06299098: Active Phase 2 study of Obesity, sponsored by Regeneron Pharmaceuticals.

NCT06299098 is a Phase 2 study of Obesity that is active but no longer recruiting, run by Regeneron Pharmaceuticals. The registered enrollment target is 1,005 participants, above the 818-participant average among 1,053 other Obesity trials with a reported enrollment target (23% higher). The trial reports 20 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06299098, a Phase 2 study of Obesity, is active but no longer recruiting, sponsored by Regeneron Pharmaceuticals.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
1,005 participants
Enrollment target
20
Study locations

Study Summary

This study is researching experimental drugs called trevogrumab and garetosmab (called "study drugs") in combination with another drug, semaglutide (Wegovy®). This study will be done in 3 parts, Part A, Part B, and Part C where different study drugs will be tested. Part A of the study is focused on healthy participants. Part B and C of the study is focused on participants with obesity. The aim of Part A of the study is to see how safe and tolerable the study drug is in healthy participants. The aim of Part B and Part C of the study is to see how safe and effective the study drug is when combined with Wegovy. Parts A, B, and C of the study are looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)

Primary Outcome

Part A

Conditions Studied

Obesity

Interventions

  • DRUG Semaglutide
  • DRUG Garetosmab
  • DRUG Trevogrumab-Part A
  • DRUG Trevogrumab-Part B and Part C
  • DRUG Matching Placebo-Part A

Study Locations (20)

California

  • Anaheim Clinical Trials - Anaheim
  • ProSciento - Chula Vista
  • Valiance Clinical Research- Huntington Park - Huntington Park
  • Velocity, San Diego - La Mesa
  • Northern California Research - Sacramento
  • Acclaim Clinical Research - San Diego
  • Metabolic Institute of America - Tarzana
  • Valiance Clinical Research - Tarzana

Florida

  • Southwest General Healthcare Center - Fort Myers
  • Westside Center for Clinical Research - Jacksonville
  • Jacksonville Center for Clinical Research - Jacksonville
  • IMA Clinical Research St. Petersburg - St. Petersburg
  • Precision Clinical Research, LLC - Sunrise
  • Clinical Research of West Florida, Inc. - Tampa
  • Clinical Research of Central Florida - Bond Clinic - Winter Haven

Alabama

  • Pinnacle Research Group - Anniston
  • Cullman Clinical Trials - Cullman

Georgia

  • Center for Advanced Research and Education - Gainesville
  • Balanced Life Health Care Solutions - Lawrenceville

Arizona

  • Foothills Research Center Cct Research - Phoenix

Trial Details

FieldValue
Enrollment Target 1,005 participants
Start Date 2024-03-13
Est. Completion 2026-10-30
Phase Phase 2
Regeneron Pharmaceuticals

280 total trials

What the registry record for NCT06299098 still lists

NCT06299098 is an interventional study that assigns participants to a tested intervention. Its 1,005 participants enrollment target places it among the larger protocols in the corpus, above the 818-participant average among 1,053 other Obesity trials with a reported enrollment target (23% higher).

The record links to 1 condition, with Obesity appearing as the primary indexed condition, and to 5 interventions - of which Semaglutide is the first listed.

NCT06299098 names 20 study sites across 5 states, led by California, Florida, Alabama.

Frequently Asked Questions

What is clinical trial NCT06299098 about?

NCT06299098 is a clinical study titled "A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss, Fat Loss, and Lean Mass Preservation". This study is researching experimental drugs called trevogrumab and garetosmab (called "study drugs") in combination with another drug, semaglutide (Wegovy®). This study will be done in 3 parts, Part A, Part B, and Part C where different study drugs will be tested. Part A of the study is focused on...

What is the current status of trial NCT06299098?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 1,005 participants. The study started on 2024-03-13. Estimated completion is 2026-10-30.

What conditions does trial NCT06299098 study?

This clinical trial studies the following conditions: Obesity.

What interventions are being tested in trial NCT06299098?

The interventions under investigation include: Semaglutide (DRUG), Garetosmab (DRUG), Trevogrumab-Part A (DRUG), Trevogrumab-Part B and Part C (DRUG), Matching Placebo-Part A (DRUG).

Who is sponsoring clinical trial NCT06299098?

This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06299098 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Obesity

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06299098's enrollment target sits among peer trials

1,005 72nd of 1053 higher than 982 of 1,053 other Obesity trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04389632 · 1,006 participants · Phase 1

    A Study of Sigvotatug Vedotin in Advanced Solid Tumors

  • NCT07191782 · 1,008 participants · NA

    Examining the Efficacy of the PRAISE With Coaching Program

  • NCT06207864 · 1,001 participants · NA

    Engagement of American Indians of Southwestern Tribal Nations in Cancer Genome Sequencing

  • NCT00018044 · 1,000 participants

    Study of Mycobacterial Infections

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT06299098, the US trial registry maintained by the National Library of Medicine. NCT06299098 (large enrollment · wide site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.